KOSDAQBiotech & Pharma038290

Macrogen

₩11,420▼ 0.70%2026-11-18 close
Market Cap
₩123.8B
Turnover
₩100M
Volume
9K
Shares out.
10.8M
PER
21.2×
PBR
0.8×
EPS
₩539
Dividend Yield
4.37%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩500 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue is growing, but quarterly profit remains thin

Macrogen's 2025 revenue of KRW 195.3 billion and a return to operating profit point to recovery, but a net loss attributable to controlling shareholders in Q3 2026 keeps sustained profitability as the open question.

  1. 1

    2025 revenue of KRW 195.3 billion was the largest year in the 2022-2025 span, up 43.8% from the prior year.

  2. 2

    Operating profit turned positive at KRW 181 million in 2025, but the operating margin of 0.1% leaves a thin cushion.

  3. 3

    Q3 2026 revenue of KRW 51.9 billion and operating profit of KRW 1.71 billion rose year on year, yet a net loss attributable to controlling shareholders of KRW 1.99 billion marked a swing back to deficit.

  4. 4

    Daishin Securities projected 2026 revenue of KRW 241.1 billion in an early-2026 report and KRW 208.3 billion in a September 2026 report.

  5. 5

    The company announced its sixth consecutive year of cash dividends and a 66.7% increase in the dividend amount, making shareholder returns a point to track alongside earnings.

02

Business structure

Macrogen was founded in 1997 from the Seoul National University genome medicine institute and operates as a genome analysis company. Its business is centered on DNA sequencing.

A business breakdown on a job-platform company profile (as of March 2026) puts DNA sequencing at 88%, oligo at 5%, microarray at 4%, and genetically engineered mouse services at 1%. Its scope is widening from contract research and clinical analysis toward consumer genetic tests and a data platform.

Daishin Securities said the Gentok test links with Samsung Health lifelog data, while the Japanese DTC service ChatGENE serves as a channel for overseas data inflow.

In April 2025 the consumer test began offering digital healthcare services on Samsung Galaxy devices, and in September 2025 the company signed an AI-based personalized care national project contract with Gangbuk Samsung Hospital. The Songdo Global Genome Center was completed in January 2026.

Overseas, Macrogen holds 54.1% of its U.S. subsidiary Psomagen, Inc., which has a clinical testing quality system based on CLIA and CAP accreditation. Its main demand source is national-level bio big data projects such as K-DNA.

Falling unit prices amid intensifying competition in sequencing equipment are seen as favorable for the cost structure of Macrogen as a service provider.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩49.1B₩1.1B2.3%
2025Q4₩56.3B₩3.6B6.5%
2026Q1₩45.3B-₩500M−1.1%
2026Q2₩51B₩700M1.4%
2026Q3₩51.9B₩1.7B3.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩138.6B₩5.3B-₩22.3B3.8%−12.4%54.8%
2023₩132.8B-₩400M-₩16.8B−0.3%−10.5%60.2%
2024₩135.8B-₩6.5B-₩7.8B−4.8%−4.8%85.8%
2025₩195.3B₩200M₩2B0.1%1.3%104.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed annual basis, revenue moved from KRW 138.6 billion in 2022 to KRW 132.8 billion in 2023 (down 4.2% year on year), then to KRW 135.8 billion in 2024 (up 2.2%) and KRW 195.3 billion in 2025 (up 43.8%).

Revenue rose for two consecutive years from 2024 through 2025, and 2025 was the largest year in the 2022-2025 span. Operating profit of KRW 5.29 billion in 2022 turned into an operating loss of KRW 423 million in 2023, and the operating loss widened to KRW 6.46 billion in 2024.

Operating profit returned to KRW 181 million in 2025, but the operating margin of 0.1% sits well below the 3.8% of 2022.

On a net income attributable to controlling shareholders basis, losses of KRW 22.3 billion in 2022, KRW 16.8 billion in 2023 and KRW 7.78 billion in 2024 gave way to a profit of KRW 2.03 billion in 2025.

Net income including non-controlling interests was a loss of KRW 202 million in 2025, which differs from the controlling-shareholder figure. The gap between the two indicates that non-controlling interests absorbed part of the loss.

Quarterly, operating profit rose from KRW 1.11 billion in Q3 2025 to KRW 3.64 billion in Q4 2025, up 226.9% quarter on quarter. Q1 2026 posted an operating loss of KRW 509 million, and Q2 2026 returned to operating profit of KRW 698 million.

Q3 2026 revenue of KRW 51.9 billion rose 5.8% year on year and operating profit of KRW 1.71 billion rose 54.0%, but the company swung to a net loss attributable to controlling shareholders of KRW 1.99 billion. Across the latest four quarters, net income attributable to controlling shareholders totaled KRW 585 million.

The debt ratio rose from 54.8% in 2022 to 104.1% in 2025, with total liabilities of KRW 179.3 billion and total equity of KRW 172.3 billion at end-2025, including KRW 157.3 billion attributable to controlling shareholders. Operating cash flow reached KRW 22.3 billion in 2025, up from KRW 10.8 billion in 2022.

05

Industry analysis

Demand for Korean genome analysis services depends heavily on the volume of national-level bio big data projects. Daishin Securities attributes the growth in 2026 to the expansion of this volume.

Because service businesses see fixed costs per unit dilute as processing volume rises, the brokerage sees volume growth translating into margin improvement.

On the equipment side, intensifying competition among sequencing equipment makers is lowering unit prices, which is favorable for a service provider that buys and runs the equipment.

Overseas, a report said the BIOSECURE Act could direct demand toward non-Chinese providers in the U.S., which would benefit the U.S. subsidiary Psomagen directly. The business is extending from genome analysis toward a data and AI-based personal health platform.

If global genomics stocks keep strengthening, interest in related Korean companies could also rise. In terms of cycle position, the brokerage views 2026 as a phase where volume expansion and cost leverage overlap after the return to quarterly profit in Q3 2025.

Within the competitive landscape, Macrogen is one of few operators combining a domestic genome service base with an overseas base, and market share data is outside the scope of this report.

06

Outlook

In a September 28, 2026 report, Daishin Securities projected 2026 revenue of KRW 208.3 billion (up 6.7% year on year) and operating profit of KRW 84 million (4.0% operating margin).

In an early-2026 report, the same brokerage had projected 2026 revenue of KRW 241.1 billion and operating profit of KRW 124 million, so the estimate has come down. Daishin Securities' September 28, 2026 report maintained a Buy rating and lowered the target price to KRW 21,000.

The brokerage said the target cut reflected a lower valuation multiple, and that the potential for profitability gains from automation and overseas subsidiary efficiency remains intact. For 2027, the same brokerage projected operating profit of KRW 18.8 billion and a 7.7% operating margin, based on NGS revenue.

To reach the full-year 2026 estimate, Q4 revenue would need to keep running above the Q3 level. The Songdo center's operational stabilization and process automation are seen as supporting profit improvement.

The company decided on a sixth consecutive year of cash dividends, and an extraordinary shareholders' meeting on December 18, 2026 will consider a capital reserve reduction. Q4 2026 results will be confirmed in the annual report, and whether the operating margin rises from 0.1% is the next checkpoint.

07

Valuation

PER
21.2×
PBR
0.8×
ROE
3.8%
EPS
₩539
BPS
₩14,059
Dividend per share
₩500

Valuation reads more accurately against recent earnings scale and book equity. The net income attributable to controlling shareholders across the latest four quarters totaled KRW 585 million, so price-to-earnings multiples are sensitive to quarterly swings.

The price-to-book ratio sits below 1x, meaning the market is not paying a premium over the KRW 157.3 billion attributable to controlling shareholders. Market capitalization is also below total equity, so book value serves as a reference line.

Cash dividends have continued for six years with a higher payout, but the dividend size is ultimately tied to earnings. The September 2026 brokerage report shows the applied valuation multiple was lowered.

Historical multiples from loss-making periods are better read in terms of the shift to profit, since operating profit moved from losses to profit over the 2022-2025 span. The debt ratio rising to 104.1% is another variable in interpreting the multiple.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Volume growth and fixed-cost dilution

Operating profit returned to profit in 2025 and continued with KRW 7 million in Q2 2026 and KRW 1.71 billion in Q3 2026. Daishin Securities sees rising volume diluting fixed costs and driving operating leverage. The September 2026 report projects 2026 operating profit of KRW 84 million.

National projects and a data platform

The Gentok test links with Samsung Health lifelog data for personalized insights, and ChatGENE in Japan serves as an overseas data channel. The September 2025 national project contract with Gangbuk Samsung Hospital adds a reference for AI-based care. Brokerage commentary says service competitiveness strengthens as data accumulates.

North American base and shareholder returns

Macrogen holds 54.1% of Psomagen, which has CLIA- and CAP-based clinical testing capabilities. Press coverage suggests Psomagen could benefit directly if BIOSECURE Act rules increase demand for non-Chinese providers. The company decided on a sixth consecutive year of cash dividends and raised the dividend amount by 66.7%.

09

Bear factors

Thin earnings cushion and quarterly volatility

The operating margin was 0.1% in 2025, below 3.8% in 2022. Quarterly results have swung, with an operating loss of KRW 509 million in Q1 2026 and a net loss attributable to controlling shareholders of KRW 1.99 billion in Q3 2026. Net income attributable to controlling shareholders over the latest four quarters totals KRW 585 million.

Downward drift in estimates and target price

Daishin Securities' 2026 revenue estimate fell from KRW 241.1 billion in an early-2026 report to KRW 208.3 billion in the September 2026 report. Daishin Securities' September 2026 report lowered the target price to KRW 21,000 and cited a lower applied multiple. Reaching the annual estimate requires a meaningful Q4 step-up relative to the disclosed first three quarters.

Financial leverage and non-controlling interest burden

The debt ratio rose from 54.8% in 2022 to 104.1% in 2025. Total liabilities of KRW 179.3 billion at end-2025 exceed total equity of KRW 172.3 billion.

Net income of KRW 202 million loss in 2025 contrasts with KRW 2.03 billion profit attributable to controlling shareholders, showing that non-controlling interests bore part of the losses.

10

Risk factors

Dependence on policy-driven volume

Growth is driven mainly by volume from national bio big data projects such as K-DNA. Changes in budgets or timing could reduce processed volume and weaken the fixed-cost dilution effect.

Because the 2026 operating leverage forecast relies on this volume assumption, project timing changes could feed directly into estimate revisions.

Equipment pricing and overseas regulation

Lower sequencing equipment prices help the cost base of a service provider, but service pricing may also fall. Replacement demand from the BIOSECURE Act is a reported outlook, and actual contract volume must be confirmed through disclosures. The U.S. subsidiary Psomagen's results depend on that outlook.

Balance sheet and subsidiary earnings volatility

The debt ratio rose to 104.1%, raising the financial burden. The gap between net income including non-controlling interests and the controlling-shareholder figure shows subsidiary results being shared with minority holders.

As Q3 2026 showed, operating profit can be positive while the net result attributable to controlling shareholders is a loss, so non-operating items and subsidiary swings need monitoring together.

11

What to watch next

  1. December 18, 2026

    Extraordinary shareholders' meeting to consider a capital reserve reduction. The outcome will show any change to the capital structure and shareholder return approach.

  2. By March 31, 2027

    Filing of the 2026 annual report. It will confirm Q4 and full-year operating margin, net income attributable to controlling shareholders, and dividend decisions.

  3. By May 15, 2027

    Filing of the Q1 2027 quarterly report. It will show whether Songdo center stabilization and automation lift margins, and how Psomagen's U.S. contract flow develops.

12

Overall view

Macrogen posted KRW 195.3 billion in 2025 revenue and a return to operating profit, signaling recovery in both top line and profit. However, the operating margin of 0.1% is thin, and Q3 2026 operating profit rose while the company swung to a net loss attributable to controlling shareholders of KRW 1.99 billion.

Bullish factors include fixed-cost dilution from national bio data project volume, the expansion of the data platform, and the U.S. base of Psomagen. Bearish factors include quarterly profit volatility, the downward drift in brokerage estimates and target price, and the financial burden from a debt ratio of 104.1%.

Daishin Securities' 2026 revenue estimate was lowered to KRW 208.3 billion, while a 2027 operating profit of KRW 18.8 billion was projected. The next checkpoints are the December 2026 extraordinary shareholders' meeting, the Q4 2026 figures in the annual report, and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. etoday.co.kr
  2. seoulwire.com
  3. macrogen.com
  4. m.pharmstock.co.kr
  5. saramin.co.kr
  6. kind.krx.co.kr
  7. alphasquare.co.kr
  8. digitaltoday.co.kr
  9. jobkorea.co.kr
  10. alphabiz.co.kr
  11. thinkpool.com
  12. markets.hankyung.com
  13. pinpointnews.co.kr
  14. littlebproject.com
  15. judal.co.kr
  16. biotimes.co.kr
  17. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis